The present invention is directed to quinoline amide compounds of formula (I)which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.本發明係關於式(I)之喹啉醯胺化合物，其為M1受體正向異位調節劑且適用於治療涉及M1受體之疾病，該等疾病諸如阿茲海默氏症(Alzheimer's disease)、精神分裂症、疼痛或睡眠障礙。本發明亦係關於包含該等化合物之醫藥組合物，及該等化合物及組合物在治療由M1受體介導之疾病中之用途。
